Poor ovarian response to gonadotrophin stimulation — The role of adjuvant treatments

Human Fertility

Volumn 5, Issue sup1, 2002, Pages S46-S52

  Keay, Stephen D ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ARGININE; CHOLINESTERASE INHIBITOR; CHORIONIC GONADOTROPIN; CLOMIFENE; DEXAMETHASONE; ESTRADIOL; FOLLITROPIN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADOTROPIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; NITRIC OXIDE; PLACEBO; PRASTERONE; PREDNISOLONE; PYRIDOSTIGMINE; SOMATOMEDIN C;

ADJUVANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GENETIC HETEROGENEITY; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; INCIDENCE; INFERTILITY THERAPY; LONG TERM CARE; OVARY CYCLE; OVARY INSUFFICIENCY; OVULATION INDUCTION; PREGNANCY; TONGUE DISEASE;

FEMALE; GONADOTROPINS; HUMANS; OVARIAN DISEASES; OVARIAN FUNCTION TESTS; OVARY;

EID: 0036129462     PISSN: 14647273     EISSN: 17428149     Source Type: Journal    
DOI: 10.1080/1464727022000199921     Document Type: Article

References (59)

1. Adashi EY, Resnick CE, D'Ercole A, Svoboda ME, Van Wyk JJ. Insulin-like growth factors as intraovarian regulators of granulosa cell function. Endocrine Reviews 1985; 6: 400 – 420
2. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Human Reproduction 2000; 15: 2145 – 2147
3. Anteby EY, Hurwitz A, Korach O, Revel A, Simon A, Finci-Yeheskel Z, Mayer M, Laufer N. Human follicular nitric oxide pathway: relationship to follicular size, oestradiol concentrations and ovarian blood flow. Human Reproduction 1996; 11: 1947 – 1951
4. Bassil S, Godin PA, Donnez J. Outcome of in vitro fertilization through natural cycles in poor responders. Human Reproduction 1999; 14: 1262 – 1265
5. Battaglia C, Salvatori M, Maxia N, Petraglia F, Facchinetti F, Volpe A. Adjuvant l-arginine treatment for in vitro fertilization in poor responder patients. Human Reproduction 1999; 14: 1690 – 1697
6. Bergh C, Hillensjo T, Wikland M, Nilsson L, Borg G, Hamberger L. Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertility and Sterility 1994; 62: 113 – 120
7. Bider D, Amoday I, Tur-Kaspa I, Livshits A, Dor J. The addition of a glucocorticoid to the protocol of programmed oocyte retrieval for in vitro fertilization — a randomized study. Human Reproduction 1996; 11: 1606 – 1608
8. Busacca M, Fusi FM, Brigante C, Bonzi V, Gonfiantini C, Vignali M, Ferrari A. Use of growth hormone-releasing factor in ovulation induction in poor responders. Journal of Reproductive Medicine 1996; 41: 1431 – 1434
9. Carlsson B, Bergh C, Bentham J, Olsson JH, Norman MR, Billig H, Roos P, Hillensjo T. Expression of functional growth hormone receptors in human granulosa cells. Human Reproduction 1992; 7: 1205 – 1209
10. Casanueva FF, Burguera B, Muruais C, Dieguez C. Acute administration of glucocorticoids: a new and peculiar stimulus to growth hormone secretion in man. Journal of Clinical Endocrinology and Metabolism 1990; 70: 234 – 237
11. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction 2000; 15: 2129 – 2132
12. Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertility and Sterility 1998; 69: 505 – 510
13. Delitala G, Tomasi P, Virdis R. Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications. Journal of Endocrinological Investigation 1988; 11: 441 – 462
14. Dlugl AM, Loy RA, Dieterle S, Bayer SR, Siebel MM. The effect of endometriomas on in vitro fertilization outcome. Journal of In Vitro Fertilization and Embryo Transfer 1989; 6: 338 – 341
15. Faber BM, Mayer J, Cox B, Jones D, Toner JP, Oehninger S, Muasher SJ. Cessation of gonadotrophin-releasing hormone agonist therapy combined with high-dose gonadotrophin stimulation yields favorable pregnancy results in low responders. Fertility and Sterility 1998; 69: 826 – 830
16. Fanchin R, de Ziegler D, Olivennes F, Taieb J, Dzik A, Frydman R. Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting ‘poor responders’ in in vitro fertilization. Human Reproduction 1994; 9: 1607 – 1611
17. Fridstrom M, Carlstrom K, Sjoblom P, Hillensjo T. Effect of prednisolone on serum and follicular fluid androgen concentrations in women with polycystic ovarian syndrome undergoing in vitro fertilization. Human Reproduction 1999; 14: 1440 – 1444
18. Gates GS, Bayer S, Siebel M, Poretsky L, Flier JS, Moses AC. Characterization of insulin-like growth factor binding to human granulosa cells obtained during in vitro fertilization. Journal of Receptor Research 1987; 7: 885 – 890
19. Hofmann GE, Scott RT, Horowitz MD, Thie J, Navot D. Evaluation of the reproductive performance of women with elevated day 10 progesterone levels during ovarian reserve screening. Fertility and Sterility 1995; 63: 979 – 983
20. Homburg R, Ostergaard H. Clinical applications of growth hormone for ovarian stimulation. Human Reproduction Update 1995; 1: 264 – 275
21. Howles CM, Loumaye E, Germond M, Yates R, Brinsden P, Healy D, Bonaventura LM, Strowitzki T. Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in vitro fertilization?. Human Reproduction 1999; 14: 1939 – 1943
22. Hugues JN, Torresani T, Herve F, Martin-Pont B, Tamboise A, Santarelli J. Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women. Fertility and Sterility 1991; 55: 945 – 951
23. Ibanez L, Potau N, de Zegher F. Ovarian hyporesponsiveness to follicle stimulating hormone in adolescent girls born small for gestational age. Journal of Clinical Endocrinology and Metabolism 2000; 85: 2624 – 2626
24. Ibrahim ZHZ, Matson PL, Buck P, Lieberman BA. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response. Fertility and Sterility 1991; 55: 202 – 204
25. Jacobs SL, Metzger DA, Dodson WC, Haney AF. Effect of age on response to human menopausal gonadotrophin stimulation. Journal of Clinical Endocrinology and Metabolism 1990; 71: 1525 – 1530
26. Jenkins JM, Davies DW, Devonport H, Anthony FW, Gadd SC, Watson RH, Masson GM. Comparison of ‘poor’ responders with ‘good’ responders using a standard buserelin/human menopausal gonadotrophin regime for in vitro fertilization. Human Reproduction 1991; 6: 918 – 921
27. Jenkins JM, Gadd SC, Anthony FW, Masson GM. Corticosteroids may act via IGF-1 to improve the response to ovarian stimulation in IVF ‘poor’ responders. British Journal of Obstetrics and Gynaecology 1994; 101: 269 – 270
28. Karande V, Gleicher N. A rational approach to the management of low responders in in vitro fertilization. Human Reproduction 1999; 14: 1744 – 1748
29. Karande VC, Jones GS, Veeck LL, Muasher SJ. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve in vitro fertilization outcome in low responder patients. Fertility and Sterility 1990; 53: 486 – 489
30. Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. British Journal of Obstetrics and Gynaecology 1997; 104: 521 – 527
31. Keay SD, Liversedge NH, Jenkins JM. Could ovarian infection impair the ovarian response to gonadotrophin stimulation?. British Journal of Obstetrics and Gynaecology 1998a; 105: 252 – 254
32. Keay SD, Barlow R, Eley A, Anthony FW, Masson GM, Jenkins JM. The relation between IgG antibodies to Chlamydia trachomatis and poor ovarian response to gonadotrophin stimulation before in vitro fertilization. Fertility and Sterility 1998b; 70: 214 – 218
33. Keay SD, Liversedge NH, Mathur RS, Akande AV, Jenkins JM. Defining poor ovarian response to gonadotrophin stimulation prior to assisted conception. Human Fertility 1999; 2: 80 – 81, F3
34. Keay SD, Lenton EA, Cooke ID, Hull MGR, Jenkins JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme. Human Reproduction 2001; 16: 1861 – 1865
35. Kemeter P, Feichtinger W. Prednisolone supplementation to Clomid and/or gonadotrophin stimulation for in vitro fertilization — a prospective randomized trial. Human Reproduction 1986; 1: 441 – 444
36. Kim C-H, Chae H-D, Chang Y-S. Pyridostigmine co-treatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization-embryo transfer. Fertility and Sterility 1999; 71: 652 – 657
37. Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JL. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertility and Sterility 1996; 65: 961 – 965
38. Lass A, Skull J, McVeigh E, Margara R, Winston RM. Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in vitro fertilization can predict poor response. Human Reproduction 1997; 12: 294 – 297
39. Levy T, Limor R, Villa Y, Eshel A, Eckstein N, Vagman I, Lidor A, Ayalon D. Another look at co-treatment with growth hormone and human menopausal gonadotrophins in poor ovarian responders. Human Reproduction 1993; 8: 834 – 839
40. Loumaye E, Billion J-M, Mine J-M, Psalti I, Pensis M, Thomas K. Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test. Fertility and Sterility 1990; 53: 295 – 301
41. Manzi DL, Thornton KL, Scott LB, Nulsen JC. The value of increasing the dose of human menopausal gonadotrophins in women who initially demonstrate a poor response. Fertility and Sterility 1994; 62: 251 – 256
42. Menashe Y, Lunenfeld B, Pariente C, Frenkel Y, Mashiach S. Can growth hormone increase, after clonidine administration, predict the dose of human menopausal hormone needed for induction of ovulation?. Fertility and Sterility 1990; 53: 432 – 435
43. Miell JP, Taylor AM, Jones J, Holly JM, Gaillard RC, Pralong FP, Ross RJ, Blum WF. The effects of dexamethasone treatment on immuno-reactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers. Journal of Endocrinology 1993; 136: 525 – 533
44. Mukherjee T, Copperman AB, Lapinski R, Sandler B, Bustillo M, Grunfield L. An elevated day 3 follicle stimulating hormone: luteinizing hormone ratio in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation. Fertility and Sterility 1996; 65: 588 – 593
45. Nargund G, Cheng WC, Parsons J. The impact of ovarian cystectomy on ovarian response to stimulation during in vitro fertilization cycles. Human Reproduction 1995; 11: 81 – 83
46. Owen EJ, Shoham Z, Mason BA, Ostergaard H, Jacobs HS. Cotreatment with growth hormone after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial. Fertility and Sterility 1991; 56: 1104 – 1110
47. Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertility and Sterility 1990; 53: 288 – 294
48. Polak de Fried E, Blanco L, Lancuba S, Asch RH. Improvement of clinical pregnancy rate and implantation rate of in vitro fertilizationembryo transfer patients by using methylprednisolone. Human Reproduction 1993; 8: 393 – 395
49. Potashnik G, Lunenfield E, Shwartz I, Glezerman M, Roberts CT, Jr, LeRoith D, Sharoni Y, Levy J. Endogenous plasma growth hormone and the occurrence of pregnancies in patients undergoing in vitro fertilization and embryo transfer with ovarian stimulation. Human Reproduction 1995; 10: 1065 – 1069
50. Rubinstein M, Marazzi A, Polak de Fried E. Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: a prospective, randomized, double-blind placebo-controlled assay. Fertility and Sterility 1999; 71: 825 – 829
51. Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility and Sterility 1997; 67: 110 – 114
52. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R, Matzner W, Ching W, Chong P. High fecundity rates following in vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reproduction 1994; 9: 2278 – 2283
53. Smotrich DB, Widra EA, Gindoff PR, Levy MJ, Hall JL, Stillman RJ. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertility and Sterility 1995; 64: 1136 – 1140
54. Stone BA, Marrs RP. Ovarian responses to menopausal gonadotrophins in groups of patients with differing basal growth hormone levels. Fertility and Sterility 1992; 58: 32 – 36
55. Suikkari A, MacLachlan V, Koistinen R, Seppala M, Healy D. Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertility and Sterility 1996; 65: 800 – 805
56. Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertility and Sterility 2000; 73: 667 – 676
57. Surrey E, Bower J, Hill D, Ramsey J, Surrey M. Clinical and endocrine effect of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertility and Sterility 1998; 69: 419 – 424
58. Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone is a better predictor of in vitro performance than age. Fertility and Sterility 1991; 55: 784 – 791
59. Tulandi T, Falcone T, Guyda H, Hemmings R, Billiar R, Morris D. Effects of synthetic growth hormone-releasing factor in women treated with gonadotrophin. Human Reproduction 1993; 8: 525 – 527